Sudarshan Pharma Industries Limited has incorporated a wholly-owned subsidiary in the United States to expand its global market presence. Sudarshan Industries Inc., also referred to as Sudarshan USA, was established on June 5, 2026, with a service address in Dover, Delaware. This strategic step is intended to enlarge the company's customer base in the USA and strengthen its international footprint.

The Board of Directors had previously approved the incorporation of this limited liability company on June 19, 2025. The company has subscribed to 1,00,00,000 shares of US $0.00001 each, aggregating to US $100, which is approximately ₹9,600. This investment represents 100.00% of the paid-up share capital of Sudarshan USA.

Subsidiary Details and Objectives

Sudarshan USA will engage in the business of buying, selling, manufacturing, and trading pharmaceuticals, antibiotics, drugs, medicines, and healthcare products. The entity will also handle neutraceuticals, ayurvedic supplements, medicinal preparations, vaccines, and Active Pharmaceutical Ingredients (APIs). The operations extend to chemical products and speciality chemicals.

The incorporation does not fall within related party transactions, and no promoter or group company holds an interest in the entity outside of the parent company. Mr. Sachin Mehta, Joint Managing Director of Sudarshan Pharma Industries Limited, has been appointed as the First Director of Sudarshan USA.

Regulatory and Financial Approvals

The acquisition required approval from the Reserve Bank of India under the Foreign Exchange Management Act, 1999. The company utilized the automatic route under the Foreign Exchange Management (Overseas Investment) Rules, 2022. The consideration for the acquisition was paid in cash, remitted following the necessary regulatory approvals.

The key details of the newly incorporated subsidiary are summarised below:

Sudarshan Pharma Industries Ltd has scheduled a meeting of its Warrants Committee for June 11, 2026, to consider the conversion of warrants into equity shares. The committee will review and approve the conversion of warrants and the allotment of the resulting equity shares to eligible applicants. This move is aimed at adjusting the company's capital structure in accordance with the terms of the warrant issuance.

The meeting is being convened pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates that companies obtain necessary approvals for alterations in their capital structure, including the conversion of securities such as warrants into equity shares. The committee's decision will finalize the number of shares to be allotted following the conversion process.

Sachin Mehta, Joint Managing Director of Sudarshan Pharma Industries Ltd, communicated the schedule to the stock exchanges. The filing confirmed that the primary agenda for the meeting is the approval of the conversion mechanism and the allotment of equity shares arising from the exercise of warrants. The company has requested the exchanges to place this information on record.

Key Meeting Details

The approval from the Warrants Committee is a procedural step required before the equity shares can be officially credited to the accounts of the warrant holders. Once allotted, these shares will increase the company's outstanding equity capital.